SP1 and melanoma: Comparisons across these four datasets showed high expression of either RelA (consensus HR = 1.47), POLE4 (consensus HR = 1.39) or SP1 (consensus HR = 1.48) was consistently associated with an increased risk of death in melanoma (Figure 4A and 4B).